NeuroPace, Inc. (NASDAQ:NPCE), a medical device company specializing in neurological disorders with a market capitalization of $439 million, has been making significant strides in the epilepsy ...

Responsive neurostimulation has also shown promising results, particularly in patients with idiopathic generalized epilepsy (IGE). A case series reported significant reductions in seizure ...

These children show myoclonic jerks and/or epilepsy with generalized tonic-clonic seizures only in response to a visual stimulus. Visually induced and spontaneous seizures, with or without a ...

The study is scheduled to commence early this year and will be followed by a subsequent proof of concept efficacy study in dogs with epilepsy. The potential new idiopathic epilepsy therapy has ...